Clinical Trial Update: A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/IIb open-label study evaluating oral panobinostat with 5-azacitidine in adults with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• 5-Azacitidine (azacitidine)
• Panobinostat (Panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-06-23